INTRODUCTION
Beta-2 glycoprotein I (β # GPI), also known as apolipoprotein H, is a lipid-binding glycoprotein that was identified in 1961 [1] . The primary structure, sequenced originally by Lozier et al. [2] , consists of 326 amino acids that are arranged into five repeating domains termed short consensus repeats, complement consensus repeats or ' sushi ' domains. Complete nucleotide sequencing by cDNA cloning has been reported for human β # GPI [3] [4] [5] [6] . The protein sequence predicted by cDNA differs significantly from that of Lozier et al. [2] . First, single amino acid substitutions were described at residues 102 (Ser Cys), 169 (Cys Asp) and 247 (Leu Val). The predicted changes at position 102 and 169 were more consistent with the invariant short-consensus-repeat structure. The substitution of leucine for valine at position 247 is a polymorphism of no structural importance [7] . Secondly, the disulphide-bond linkages in the fifth domain were determined to be between cysteine residues at positions 245 and 296 (Cys 1 4), 281 and 306 (Cys 2 5) and 288 and 326 (Cys 3 6). Lastly, cDNA sequencing predicted only four asparagine-linked glycosylation sites [3, 5] based on the Asn-Xaa-Ser\Thr sequences at positions 143, 164, 174 and 234 in domains III and IV. Carbohydrate contributes almost 20 % of the apparent molecular mass of 50 kDa, and studies have shown human β # GPI to be partially sialylated and galactosylated with bi-antennary and triantennary glycans [8] . More recently, a proportion of sialic acid and galactose was also found to be O-linked, probably to serine or threonine, at unknown locations within the β # GPI molecule [9] . Isoelectric-focusing studies [10, 11] reveal β # GPI to be a heterogeneous molecule with five major and up to five minor Abbreviations used : β 2 GPI, beta-2 glycoprotein I ; AnPL, anionic phospholipid(s) ; AS, ammonium sulphate ; PA, perchloric acid ; CL, cardiolipin. 1 To whom correspondence should be addressed (e-mail T.Brighton!unsw.edu.au).
preparations for anionic phospholipids are obtained when comparing anionic phospholipids immobilized to a solid-phase versus phospholipid assembled in unilamellar vesicles, (iv) that the integrity of the fifth domain of β # GPI is important for binding immobilized anionic phospholipid but not especially important in binding vesicular anionic phospholipid, and (v) that β # GPI preparations with differing isoelectric species content bind anionic phospholipids differently, suggesting that varying glycosylation and\or protein polymorphisms impact upon phospholipid binding. These results highlight the importance of assessing the determinants of the interaction of β # GPI with anionic phospholipids assembled in unilamellar vesicles.
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isoforms. The structural basis of this microheterogeneity is controversial. Variation in glycosylation, specifically sialylation, has been proposed as the structural difference between isoelectric species [10, 11] . In contrast, more recent reports suggest that specific polypeptide polymorphisms account for this heterogeneity [12] .
Whereas the physiological role of β # GPI remains unclear, many studies suggest that it may be a natural anti-coagulant. β # GPI has been demonstrated in itro to inhibit intrinsic pathway activation [13] , and to inhibit tenase [14] and prothrombinase [15] activities upon the surface of activated platelets and synthetic phospholipid vesicles. Plasma levels of β # GPI have been shown to fall in disseminated intravascular coagulation [13, 16] , consistent with consumption of β # GPI in this thrombotic process. The anti-coagulant action most probably resides in the ability of β # GPI to bind negatively charged surfaces including anionic phospholipids (AnPL) [17] . The lipid-binding properties of β # GPI have, however, only been characterized partially. A putative lipid-binding site in the fifth repeating domain of β # GPI has been proposed [18] . This site consists of a highly positively charged six-amino acid sequence Lys-Asn-Lys-Glu-Lys-Lys (residues 282-287) located in the fifth domain of β # GPI. Computer modelling of β # GPI, based on sequence homology with complement consensus repeat 13 of human Factor H, suggests that this sequence is surface exposed and thus suited to be a binding site [18] . Cleavage within the fifth domain completely abrogated binding of β # GPI to AnPL bound to a solid phase [19] . Studies with various synthetic peptides spanning the fifth domain of β # GPI confirm that a binding site for solid-phase AnPL is contained within the sequence Cys-281-Cys-288 [20] . Site-directed-mutagenesis studies have also demonstrated the importance of this region in binding to AnPL bound to a solid phase [21, 22] . More recently, two polymorphisms in the fifth domain (Cys-306 Gly-306 and Trp-316 Ser-316) have been shown to influence binding to AnPL coated to a solid phase [23] . These are currently the only known structural determinants of β # GPI that influence its binding to AnPL. Additionally, most studies have looked exclusively at binding to AnPL coated to a solid phase.
In this study we have investigated the affinity of various preparations of β # GPI for AnPL assembled in unilamellar vesicles. The affinity for AnPL in this more physiological form is compared with AnPL coated to a solid phase. Substantial differences were found between solid-phase and bilayer phospholipid-binding assays. We confirm that proteolysis in the fifth domain is an important determinant of binding to solidphase AnPL but not as important for binding bilayer AnPL. Our results suggest that differing isoelectric species of β # GPI, some probably induced during purification, have variable affinities for AnPL. These results highlight the importance of assessing the binding by β # GPI of AnPL in physiological binding assays for determining a physiological role for this glycoprotein.
MATERIALS AND MATERIALS

Purification of β 2 GPI
Several preparations of human β # GPI were made, including β # GPI from perchloric acid (PA) precipitation of plasma (PA peaks 1, 2 and 3), β # GPI from ammonium sulphate (AS) precipitation of plasma in the presence of proteolytic inhibitors (AS peaks 1 and 2), and a β # GPI purified from plasma by affinity chromatography on a cardiolipin (CL) solid phase (CL-1). The PA-derived β # GPIs were made as described previously [16] . Briefly, 10 l of normal human plasma from several donors was first dialysed against 0.15 M NaCl\0.01 M Tris\HCL (pH 7.0 ; dialysis buffer) overnight. To this dialysed plasma 70 % PA was added dropwise while stirring at room temperature to a final concentration of 3-5 %. After 15 min the preparation was centrifuged, and the supernatant containing β # GPI was then pHadjusted to 7.3-7.6 with saturated Na # CO $ solution and then dialysed overnight against the dialysis buffer. The dialysed supernatant was then applied to a heparin-Sepharose CL-4B column (Pharmacia, Uppsala, Sweden) equilibrated in dialysis buffer, and bound protein eluted with 0.5 M NaCl\0.01 M Tris\HCl (pH 7.0). The β # GPI-containing fractions, as assessed by SDS\PAGE and β # GPI ELISA, were pooled, concentrated over a PM-10 Amicon membrane (Amicon Division, W. R. Grace & Co., Beverley, MA, U.S.A), and then subjected to sizeexclusion chromatography using Sephacryl S-200 (Pharmacia) in the same buffer. Fractions containing β # GPI were pooled and dialysed against 0.05 M sodium acetate\0.05 M NaCl (pH 4.8). This preparation was then applied to an S-Sepharose fast-flow (Pharmacia) column which was developed with a linear gradient with 0.05 M sodium acetate\0.5 M NaCl (pH 5.2). Six β # GPIcontaining peaks were resolved and each peak was pooled separately, dialysed against distilled water and concentrated in an Amicon concentrator (Amicon Division) with a PM-10 membrane to a final concentration between 600-1500 µg\ml. In order of elution the maximum absorbance at 280 nm of the peaks were 0.078, 0.398 (PA-1), 0.142, 0.297, 1.055 (PA-2) and 0.07 (PA-3).
Because PA is potentially damaging to polypeptide and carbohydrate moieties, an AS purification method of β # GPI was developed. Additionally, because of proteolysis in the fifth domain of β # GPI influencing its phospholipid binding, purification was performed in the presence of a cocktail of proteolytic inhibitors. In preliminary experiments it was found that 90 % of plasma β # GPI was precipitated in two separate portions between AS saturations of 30-50 % (containing 38 % of total plasma β # GPI) and 60-70 % (containing 57 % of total plasma β # GPI). As it was not known if these two portions were identical they were purified separately. Normal human serum from healthy blood donors was first pooled and then cooled to 4 mC. Proteolytic inhibitors that were added included benzamidine hydrochloride (20 µM, Sigma), aprotonin (5 µM, Trasylol2, 500 000 kallikreininactivating units\50 ml, Bayer Australia), PMSF (2 mM, Sigma) and disodium EDTA (10 mM). AS was added to achieve stepwise final concentrations of 30, 50 and 70 %. After each addition the plasma was stirred continuously for 30 min at 4 mC. The precipitate was then harvested by centrifugation in 250-ml aliquots in a Beckman refrigerated centrifuge at 10 800 g, and the supernatant was returned to 4 mC for further precipitation steps as detailed. The collected precipitates for 30-50 % and 50-70 % (labelled AS-1 and AS-2 respectively) were then extensively dialysed separately against distilled water and then against 0.15 M NaCl\0.01 M Tris\HCl (pH 7.3). The dialysed preparations were then applied to heparin-Sepharose, size-exclusion chromatography and, finally, anion-exchange chromatography as described previously. At anion-exchange, single peaks of β # GPI were eluted from the column. Finally the purified β # GPI was dialysed against distilled water and concentrated in an Amicon concentrator (Amicon Division) with a PM-10 membrane to a final concentration of 1500-6000 µg\ml. The final preparations were aliquoted and stored at k80 mC until use.
The final preparation of β # GPI (CL-1 or CL β # GPI) was copurified with anti-CL antibodies from plasma as described previously [24] . This plasma was obtained from a single patient with venous thrombosis, and the native plasma was positive for both lupus anti-coagulant and anti-CL antibodies. The β # GPI and anti-CL antibody containing eluate from the CL-affinity column was dialysed against PBS (Dulbecco ' A ', Oxoid, Unipath, Hampshire, U.K.) and applied to anti-human IgGagarose (Sigma Immunochemicals, A-3543). Fall-through fractions were collected and dialysed against 0.05 M sodium acetate\0.05 M NaCl (pH 4.8). This preparation was then chromatographed on S-Sepharose fast-flow (Pharmacia) as described previously. A number of elution peaks were obtained, with a major protein peak that eluted at 0.53 M NaCl. This peak was collected and dialysed against distilled water and concentrated over a PM-10 membrane in an Amicon concentrator to a final concentration of 600 µg\ml. The final preparations were aliquoted and stored at k80 mC until use.
Characterization of β 2 GPI preparations
The various preparations of β # GPI were characterized by SDS\ PAGE under reducing and non-reducing conditions, and were subjected to cation exchange, chromatofocusing and N-terminal sequencing. Samples for SDS\PAGE were run on 10 % resolving and 4 % stacking gels with 2-mercaptoethanol as reducing agent and stained with Coomassie Brilliant Blue. Cation exchange was performed using an FPLC system (Pharmacia) and a Mono-S HR 5\5 1-ml column (Pharmacia). Fractions containing 2 mg of each β # GPI preparation were dialysed against 0.05 M sodium acetate\0.05 M NaCl (pHu 4.8). These preparations were then applied at 1 ml\min and resolved with a linear gradient with 0.05 M sodium acetate\1.0 M NaCl (pH 5.2). Each preparation resolved as a single peak and the salt concentration at resolution was recorded. Chromatofocusing was performed using an FPLC system (Pharmacia) and a Mono-P HR 5\5 1 ml column (Pharmacia). The column was cleaned and equilibrated according to the manufacturer's instructions. The β # GPI preparations were dialysed against 0.25 M diethanolamine (pH 9.5), and a minimum of 1 mg of each preparation in a final volume of 500 µl was loaded at a flow rate of 0.5 ml\min. After washing with a minimum of 30 ml of loading buffer, bound protein was allowed to elute sequentially with 25 ml of buffer A [5 ml of Polybuffer 96 (Pharmacia) in 100 ml of distilled water (pH 6.0)] and then 20 ml of buffer B [10 ml of Polybuffer 74 (Pharmacia) in 100 ml of distilled water (pH 4.0)]. This combination of buffers allowed chromatofocusing to be performed over a pH range from 9.5 to 4.0. Analysis of the original UV chromatographs was performed by accompanying FPLCdirector4 software. Additionally, on each 0.5 ml fraction the protein concentration was determined by spectral absorbance at 280 nm, and the pH was measured to three decimal places with a Micro 2 pH\Ion Meter (EDT Instruments, CHK Engineering, Ermington, Sydney, Australia) with a Sensorex Epoxy Sealed Reference pH probe (CHK Engineering) and a temperature probe. The N-terminal sequence of each preparation was determined kindly by Dr. R. Simpson and colleagues (Ludwig Institute for Cancer Research, Melbourne, Australia) after preparative HPLC on a Nova-Pak C ") column equilibrated with 0.1 % trifluoroacetic acid and eluted with 0.1 % trifluoroacetic acid\70 % acetonitrile. The extent of cleavage in the fifth domain for each preparation of β # GPI was estimated from this analysis.
Binding of β 2 GPI to solid-phase phospholipids
The binding of the various β # GPI preparations to phospholipids coated to a solid phase was performed. Aliquots of the various β # GPI preparations were iodinated using iodobeads (Pierce, Rockford, IL, U.S.A.) as per the manufacturer's instructions. In each iodination, 50 µg of β # GPI was combined with one iodobead and 5 µl of Na"#&I in a total reaction volume of 150 µl. After 15 min of incubation the iodinated protein was separated from free "#&I on a 10 ml Bio-Rad desalting column (Bio-Rad PDG6) equilibrated with 0.1 M phosphate buffer (pH 7.0)\5 mg\ml BSA. Microtitre plates (Nunc High-Binding Break Apart) were coated with 30 µl per well of 30 µg\ml solution of either bovine phosphatidylserine or bovine phosphatidylcholine (Sigma) in ethanol. The plates were wrapped in foil and the liquid allowed to evaporate overnight at 4 mC. The plates were blocked with 200 µl of 1% milk powder\0.5 % BSA in PBS for 1 h at room temperature and then washed three times with 0.5 % BSA in PBS. The various "#&I-labelled β # GPI preparations diluted in PBS were then added with and without unlabelled β # GPI in a total reaction volume of 100 µl. After incubation at room temperature on a plate shaker for 60 min the supernatant was drained and the plate washed gently, once, with PBS. Total and bound radioactivity was determined by counting individual wells in a Packard Crystal II γ-radiation counter. All binding experiments were performed in duplicate.
The dissociation constants for the interaction of "#&I-β # GPI (K H ) and unlabelled β # GPI (K C ) with immobilized phospholipid are described by eqn. (1). [25] . The resulting equation is a quadratic in terms of [H:PL] as described by eqn (2).
The characterization of the binding was performed by two series of experiments. First, the affinity of "#&I-β # GPI to immobilized phospholipid (K H ) was estimated from experiments that measured the binding of a range of "#&I-β # GPI concentrations to a fixed concentration of immobilized phospholipid. Typically 5-10 % of the total "#&I-β # GPI added bound to the immobilized phospholipid. Secondly, the affinity of unlabelled β # GPI for immobilized phospholipid (K C ) was estimated from experiments measuring the binding of a fixed concentration of "#&I-β # GPI (usually 100 000 c.p.m. added) to immobilized phospholipid as a function of unlabelled β # GPI concentration. Data were fitted to eqns. (1) and (2) by non-linear least-squares regression (Scientist software ; Micromath, Salt Lake City, UT, U.S.A.).
Binding of β 2 GPI to phospholipid vesicles
Preparation of synthetic phospholipid vesicles
Large unilamellar vesicles were prepared as described by Mimms et al. [26] , with minor modification. A total of 20 mg of bovine phosphatidylserine and bovine phosphatidylcholine (Sigma) were combined in a molar ratio of 1 : 3 and dried to a thin film on a borosilicate glass tube under a stream of nitrogen and then vacuum dried for a further 2 h. The dried lipid was then dissolved by vortexing in 0.5 ml of 1.1 M n-octyl-β--glucopyranoside (Sigma), which was then removed by dialysis at room temperature on a magnetic stirrer against 1 litre of 50 mM Hepes\0.125 M NaCl\0.02 % sodium azide (pH 7.4 ; binding buffer) per day for 4 days. The supernatant was mixed periodically by pipetting, and after 4 days it became quite turbid. The resulting vesicles were isolated by gel filtration on a Sepharose CL-2B column (Pharmacia) equilibrated with the binding buffer and fractions were collected after measuring absorbance at 450 nm. The phospholipid concentration was determined by an assay for inorganic phosphate [27] . Flow-cytometric analysis on Becton FacStar confirmed the average diameter of the vesicle preparation to be approx. 250 nm compared with 2 µm standard microspheres.
Competitive binding model
A competitive model of binding was modelled on that described by Olson et al. [25] using the technique of quantitative affinity chromatography. In this model the partitioning under equilibrium conditions of the ligand β # GPI was determined by its affinities for binding sites on the affinity matrix heparinSepharose or on a soluble competitor (e.g. phospholipid vesicles or soluble heparin). Initial experiments were performed to characterize the affinity (K P ) of the ligand β # GPI, L, for the affinity matrix heparin-Sepharose, P. Experiments were then repeated in the presence of a soluble competitor, C, and an estimate of the affinity of β # GPI for the soluble competitor (K C ) could be derived. The interactions of β # GPI with the affinity matrix heparin-Sepharose and the soluble competitor are described by : 
where
and where P T is the derived maximum number of binding sites for β # GPI on heparin-Sepharose, L T is the total concentration of β # GPI and C T is the total concentration of competitor. The model assumes (i) that the interactions of β # GPI with the affinity matrix and competitor are strictly competitive, (ii) that β # GPI binds either the affinity matrix or the soluble competitor but not both simultaneously, and (iii) that β # GPI has only one binding site for either the affinity matrix or the soluble competitor. Data were fitted to eqns. (3) and (5) by non-linear least-squares regression (Scientist software, Micromath).
Competitive binding experiments
All binding experiments were performed in 1.5-ml microcentrifuge tubes (Eppendorf, Amrad, Australia) at room temperature on a mixing wheel. Heparin-Sepharose slurry was obtained from Pharmacia. The centrifuge tubes were precoated overnight at 4 mC with 10 mg\ml of poly(ethylene glycol) 20 000 (Sigma). Preliminary experiments were performed to determine the time to equilibrium binding to heparin-Sepharose, and the amount of heparin-Sepharose required for substantial β # GPI binding. Binding was 90 % complete within 10 min (results not shown) and, for all experiments, 20-min incubations were selected. The amount of heparin-Sepharose was 30 µl of a well-mixed 1-in-5 slurry of matrix in binding buffer unless otherwise stated. Total reaction volume was 500 µl and all experiments were performed in duplicate. For binding experiments in the absence of competitor, 30 µl of either buffer (control) or heparinSepharose slurry was added to 470 µl of binding buffer with a final β # GPI concentration of 30 µg\ml. After 20 min of mixing, the microcentrifuge tubes were centrifuged for 10 s at 13 000 g (Microfuge), and 20-µl samples (in triplicate) of supernatant were added to the wells of a microtitre plate (Linbro flatbottomed microtitre plate, ICN Pharmaceuticals). Free β # GPI concentration was measured by protein assay (BCA kit, Pierce). After sampling, known amounts of β # GPI were added in 60 µl of buffer and the microcentrifuge tubes returned to the mixing wheel. As many as nine stepwise additions of β # GPI were performed. For binding experiments in the presence of competitor, a similar experimental design was used. In a total reaction volume of 500 µl and fixed total concentration of β # GPI, the concentration of a competitor was increased in a stepwise fashion. In some experiments the total concentration of β # GPI was maintained by addition of further β # GPI. Free ligand concentration was measured in triplicate as detailed previously. Controls performed with these experiments included the addition of the same volume of buffer in the place of competitor. In all experiments, bound ligand concentrations were obtained by subtraction of measured free concentrations from the known total concentrations. Experiments with and without competitor were also performed in the absence and presence of 2.0 mM CaCl # . In order to maintain constant ionic strength in these experiments the calcium was introduced by appropriate mixtures of the binding buffer and a buffer containing 41.7 mM CaCl # in 50 mM Hepes\0.02 % sodium azide (pH 7.4).
Direct binding experiments
Further experiments were performed to assess directly the binding of the various β # GPI preparations to synthetic phospholipid vesicles using an ultracentrifuge method (Airfuge, Becton, Australia). Preliminary experiments were performed to determine the time required to sediment the synthetic phospholipid vesicles (results not shown). After 25 min of centrifugation, 95 % of total phospholipid in the synthetic-vesicle preparation was sedimented. Wells of a 96-well microtitre plate were precoated with 10 mg\ml of poly(ethylene glycol) 20 000 in binding buffer overnight at 4 mC. In a total reaction volume of 200 µl\well, a range of concentrations of various β # GPI preparations were incubated with two different concentrations of phospholipid vesicles for 40 min at room temperature on a plate shaker. Experiments were performed in the absence and presence of 2.0 mM CaCl # as described previously. After incubation, 20-µl aliquots (in triplicate) were added to a microtitre plate for determination of total β # GPI concentration, and the remaining mixture centrifuged in polyallomer tubes (Becton). After centrifugation, 20-µl aliquots of the supernatant (in triplicate) were added to a microtitre plate for determination of free β # GPI concentration. The dissociation constants for the interaction of β # GPI (K D ) with immobilized phospholipid are described by :
where [β # GPI], [PL] and [β # GPI:PL] are the concentrations of free β # GPI, free phospholipid and β # GPI-phospholipid complexes respectively, and χ is the number of binding sites for β # GPI on phospholipid. Phospholipid concentrations were expressed in terms of a derived concentration of surface-exposed phosphatidylserine, which was calculated to be 13.1 % of the total phospholipid concentration. This calculation assumes a random distribution of phosphatidylserine to either inner or outer leaflets of the lipid bilayer, and is the multiplication of the molar ratio of phosphatidylserine (a quarter of the total phospholipid), and an estimate of the amount of phosphatidylserine surface exposed based on the geometry of the vesicle (52.46 % for vesicles with an external diameter of 250 nm and a bilayer thickness of 6 nm). Data were fitted to eqn. (6) by non-linear least-squares regression (Scientist software, Micromath) to obtain the dissociation constant for PL (K D ).
RESULTS
Characterization of various β 2 GPI preparations
The physical characteristics of the various β # GPI preparations are summarized in Table 1 . The preparations varied in molecular mass by approx. 6 kDa under both non-reducing and reducing
Table 1 Summary of physical characteristics of β 2 GPI preparations
The first column refers to the method of purification of β 2 GPI ; PA-1 PA-2 and PA-3 were obtained from PA precipitation of plasma, AS-1 and AS-2 were from AS precipitation of plasma and CL-1 was from affinity chromatography of plasma (see the text for details). Molecular masses were determined by SDS/PAGE. Cleavage data were obtained from N-terminal sequencing. conditions with PA-1 the largest and PA-3 the smallest ( Figure  1) . Most of the β # GPI preparations eluted from the anionexchange column between 0.52 and 0.54 M NaCl with the exception of PA-1, which eluted at 0.441 M NaCl. There was a significant inverse correlation between molecular mass under reducing conditions and elution from Mono S (Spearman's correlation, r l k0.954, P l 0.019).
N-terminal sequencing confirmed that all preparations were β # GPI and that there were varying degrees of proteolysis at Lys317\Thr-318 or Ala-314\Phe-315 as described previously [21] . There was no correlation between size on SDS\PAGE and degree of proteolysis in the fifth domain of β # GPI. PA-1, the largest by SDS\PAGE, was actually the most significantly cleaved preparation (about 50 % cleaved), whereas the other preparations, which varied between 2.6 and 22.4 % cleavage, were smaller in size.
Chromatofocusing experiments revealed significant differences in isoelectric species content between the various β # GPI preparations (Figure 2) . Analysis of the original UV chromatographs revealed many more protein peaks than apparent in Figure 2 . This was especially seen for the PA preparations, where there were often 20 or more small chromatographic peaks, suggesting complex modifications of the β # GPI preparations (results not shown). In general there was a correlation between decreasing size on SDS\PAGE (reducing or non-reducing conditions), elution at higher salt concentrations from anion exchange and isoelectric species of high pH.
Binding of β 2 GPI to AnPL
A representative displacement of radiolabelled β # GPI from solidphase AnPL by unlabelled β # GPI is presented in Figure 3 . The
Table 2 Comparison of cleavage in the fifth domain of β 2 GPI with the affinities for heparin, and immobilized and vesicular AnPL
The first column refers to the method of purification of β 2 GPI ; PA-1 PA-2 and PA-3 were obtained from PA precipitation of plasma, AS-1 and AS-2 were from AS precipitation of plasma and CL-1 was from affinity chromatography of plasma (see the text for details (Figure 4a ), in the presence of soluble heparin (Figure 4b ) and in the presence of synthetic phospholipid vesicles (Figure 4c ) is illustrated. Binding of all β # GPI preparations to heparin-Sepharose in the absence of competitors was demonstrable. The binding isotherms were generally in accordance with eqn. (3), although in the absence of calcium the binding isotherm for PA-2 was slightly sigmoidal. The binding isotherms for the competition experiments with heparin fitted well with the mathematical model proposed for all preparations. The calculated affinities of the various β # GPI preparations for either the affinity matrix or soluble heparin were similar (Pearson's correlation, r l 0.989, P l 0.007). The elution from Mono-S was weakly inversely correlated with affinities of the various β # GPI preparations for heparin-Sepharose (Spearman's correlation, r l k0.761, P l 0.089). The affinity of PA-1 for heparin was an order of magnitude less than the other preparations of β # GPI. In contrast, the binding isotherms of competition experiments with synthetic phospholipid vesicles with all the β # GPI preparations studied could not be fitted with the proposed model of binding (as illustrated in Figure 4c ). The shapes of the curves suggested complex or co-operative binding. Nevertheless, all β # GPI preparations bound synthetic phospholipid vesicles to some degree, including PA-1.
Direct binding assays of β # GPI to solution-phase phospholipid vesicles were performed for most of the preparations. Representative data for these experiments are illustrated in Figure 5 with preparation PA-3. The dissociation constants of the β # GPI Microheterogeneity of beta-2 glycoprotein I preparations for solution-phase phospholipid vesicles were all similar and ranged between 0.4 and 2 µM (Table 2) . Stoichiometry for the interaction of β # GPI and phosphatidylserine from direct binding assays was estimated as follows. The size of unilamellar vesicles averaged 250 nm by comparison with 2 µm calibrated beads. Based on the experimentally derived maximal available binding sites, the phospholipid concentration, and the geometry of the unilamellar vesicle, one molecule of β # GPI occupied approximately 70 molecules of phosphatidylserine exposed in the outer leaflet of the vesicle. The affinity of PA-1 for vesicular phospholipid was an order of magnitude weaker than the other preparations. Affinity of the various β # GPI preparations for vesicular phospholipid was correlated weakly with elution from Mono-S (Spearman's correlation, r l k0.984, P l 0.088), molecular mass (r l k0.996, P l 0.085) and affinity to heparinSepharose (r l 0.99, P l 0.162), but not with the percentage of cleavage in the fifth domain (r l 0.5, P l 0.5).
DISCUSSION
In this study, a variety of β # GPI preparations were purified from plasma that differed significantly in their molecular mass, elution profiles from anion-exchange column and isoelectric-species content. The affinity of these preparations for AnPL vesicles was not well correlated with the degree of cleavage in the fifth domain, but instead correlated broadly with decreasing molecular mass, tighter binding to the anion-exchange column and more basic isoelectric-species content. Our results are consistent with varying degrees of glycosylation, most likely induced during purification, influencing affinity for AnPL. Additionally, the results of this study highlight two very important considerations in the study of β # GPI binding to AnPL, namely the presentation of AnPL and the structural integrity of β # GPI preparations used in the binding assays.
The affinities for AnPL in this study are weaker than found by Wurm [17] but consistent with several other investigators [20, 21, 28, 29] . The variation in estimates of affinity of β # GPI for AnPL in these studies is possibly attributable to many factors but probably relates mostly to varying buffer conditions. The stoichiometry calculated for AnPL vesicles in this study (one β # GPI : 70 phosphatidylserines) is similar to that reported by Willems et al. [30, 31] of one β # GPI : 75 lipid molecules.
